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Abstract
Background: To investigate influencing factors of the metastatic lymph nodes ratio (MLR) and
whether it is related to survival in patients with gastric adenocarcinoma.
Methods:  We retrospectively evaluated the clinical features of 121 patients with gastric
adenocarcinoma enrolled in our hospital between 2000 and 2007. The receiver operating
characteristic (ROC) curve was used to determine the cutoff of the MLR, and CK20
immunohistochemical staining was used to detect micrometastasis of the lymph nodes.
Results: The areas under the ROC curve of MLR used to predict the death of 3-year and 5-year
postoperative patients were 0.826 ± 0.053 and 0.896 ± 0.046. Thus MLR = 30.95% and MLR =
3.15% were designated as cutoffs. The MLR was then classified into three groups: MLR1
(MLR<3.15%); MLR2(3.15% ≤ MLR ≤ 30.95%); and MLR3 (MLR>30.95%). We found that patients
with a higher MLR demonstrated a much poorer survival period after radical operation than those
patients with a lower MLR (P = 0.000). The COX model showed that MLR was an independent
prognostic factor (P = 0.000). The MLR could also discriminate between subsets of patients with
different 5-year survival periods within the same N stage (P < 0.05). The MLR has been shown to
be 34.7% (242/697) by HE staining and 43.5% (303/697) by CK staining (P = 0.001). The
clinicopathological characteristics of lymph vessel invasion and the depth of invasion could
significantly affect the MLR.
Conclusion: MLR is an independent prognostic factor in gastric cancer. The combined ROC curve
with MLR is an effective strategy to produce a curve to predict the 3-year and 5-year survival rates.
Background
The metastatic lymph nodes ratio (MLR, N ratio) is a pow-
erful independent prognostic factor in gastric cancer, even
when only a few lymph nodes metastases were found [1-
6]. The MLR reflects the efficacy of the resection of lymph
nodes, which is the best method to prevent stage migra-
tion [3,4]. However, the criteria for MLR classification are
controversial. In order to investigate the relationship
between MLR and prognosis, N stage, and clinical charac-
teristics, we used a receiver operating characteristic curve
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(ROC curve) to determine the MLR cutoff. Additionally,
the influence of MLR on micrometastasis was also evalu-
ated.
Methods
Patients
Between 2000 and 2007, 121 patients with gastric adeno-
carcinoma were enrolled in this study from the Depart-
ment of General Surgery, No. 3 People's Hospital,
Shanghai Jiao-Tong University School of Medicine. All
patients were underwent a curative gastrectomy and none
of the patients received preoperative treatments. These
patients consisted of 77 men and 44 women, ranging in
age from 29 to 82, with a median age of 64. Total gastrec-
tomy was performed in 9 patients, distal subtotal gastrec-
tomy in 90 patients, and proximal subtotal gastrectomy in
22 patients. Additionally, 2 patients underwent D1 lym-
phadenectomy, 110 patients underwent D2 lym-
phadenectomy, and 9 patients underwent D3
lymphadenectomy. Postsurgery pathological examination
showed 16 early adenocarcinomas, 4 fungating type ade-
nocarcinomas, 16 ulcerative type adenocarcinomas, 71
invasion ulcerative type adenocarcinomas, and 14 diffuse
infiltrative type adenocarcinomas. All clinicopathological
profiles were evaluated in accordance with the criteria of
the Japanese Gastric Cancer Association [7]. Moreover, N
stage was also evaluated according to the TNM classifica-
tion of the 6th edition criteria of the International Union
against Cancer (UICC) [8]. Patient follow-up ended on
April 30, 2008 and the mean follow-up was 23 months.
During the follow-up period, 46 patients died of recur-
rence or metastasis, 6 patients died of other diseases, and
20 patients were lost to follow-up. The survival time
ranged from 6 to 93 months.
Immunohistochemistry
CK20 immunohistochemical staining and hematoxylin-
eosin (HE) staining were performed on 695 consecutive
lymph node sections from 45 gastric cancer patients. The
tissue sections were deparaffinized, dehydrated, and incu-
bated in 3% hydrogen peroxide to block endogenous per-
oxidase activity. For the purpose of antigen retrieval,
samples were microwaved for 10 minutes and were then
washed with PBS. Immunohistochemical staining was
performed with mouse monoclonal antibody against
human CK20 primary antibodies (Changdao, Shanghai,
China). Positive controls consisted of gastric cancer histo-
logical sections (Changdao, Shanghai, China), and nega-
tive controls used PBS in place of the primary antibody.
Survival curves of patients in different MLR groups Figure 2
Survival curves of patients in different MLR groups.
ROC curve of MLR for predicting survival rate Figure 1
ROC curve of MLR for predicting survival rate. A. For predicting the 3-year survival rate; B. For predicting the 5-year 
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Criterion of lymph node micrometastasis
CK20 is expressed in the cytoplasm. Lymph node sections
with an N0 of HE staining, positive CK20 immunohisto-
chemical staining, and a tumor diameter in the lymph
nodes ranging from 0.2 to 2 mm were defined as lymph
node micrometastasis. The results above were analyzed by
two pathologists.
Statistical analysis
All statistical calculations were performed using the SPSS
13.0 statistical software. ROC curves were used to assess
the accuracy of the MLR prediction survival. Comparison
of the MLR with CK20 immunohistochemical staining
and HE staining was examined with a χ2 test. Patient sur-
vival was analyzed using the Kaplan Meier product limit
method. The log rank test was used to evaluate the differ-
ence between groups. The relationship between MLR and
clinical characteristics was examined with the Mann-Whit-
ney U test. Statistical significance was defined as P < 0.05.
Results
Postsurgery survival rate
Of all patients, the postsurgery 1-year to 7-year survival
rates were 74%, 50%, 40%, 29%, 17%, 13%, and 8%,
respectively.
Table 2: Multivariate risk analysis of 121 gastric adenocarcinoma patients.
Characteristics B S.E. Wald df Sig. Exp (B) 95.0%(CI))
Lauren type 0.901 0.439 4.218 1 0.04 2.462 1.042 – 5.819
Depth of invasion 0.684 0.223 9.397 1 0.002 1.981 1.280 – 3.067
MLR 1.030 0.261 15.610 1 0.000 2.801 1.680 – 4.668
Table 1: Influence of clinicopathological characteristics on the prognosis in 121 gastric adenocarcinoma patients.
Characteristics Samples Five-year survival (%) Log-rank
(X2value)
P value
Gender (male/female) 77/44 35.5/49.5 0.527 0.468
Lauren type
Intestinal type 109 46.1 6.322 0.012
Diffuse type 12 0
Type of histology
1–2 75 40.5 0.000 0.990
34 6 4 0 . 0
Lymphatic vessel invasion
Negative 54 60.6 14.199 0.000
Positive 67 18.3
Blood vessel invasion
Negative 100 43.7 13.455 0.000
Positive 21 28.8
Lymph nodes metastasis
Negative 44 79.0 24.919 0.000
Positive 77 13.0
Depth of invasion
T1 18 94.1 25.835 0.000
T2 31 56.0
T3 31 36.7
T4 41 0
N stage (UICC)
N0 43 78.9 34.320 0.000
N1 44 22.1
N2 24 0
N3 10 0
N stage (JRSGC)
N0 42 78.9 38.976 0.000
N1 38 12.6
N2 31 16.4
N3 10 0
MLR
MLR1 43 78.9 36.575 0.000
MLR2 20 32.7
MLR3 58 0Journal of Experimental & Clinical Cancer Research 2009, 28:55 http://www.jeccr.com/content/28/1/55
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ROC curve analysis correlation between MLR and survival
After excluding from the original 121 patients that had died
of other diseases or were lost to follow-up in 3 years, the
ROC curve was drawn according to the survival of the
remaining 63 patients (Figure 1A). Similarly, after exclud-
ing the patients that had died of other diseases or were lost
to follow-up in 5 years, the ROC curve was drawn according
to the survival of the remaining 49 patients (Figure 1B). The
areas under the curves described above were 0.826 ± 0.053
(95% CI: 0.723 – 0.929) (P = 0.000) for the three-year sur-
vival ROC curve and 0.896 ± 0.046 (95% CI: 0.806 –
0.986) (P = 0.000) for the five-year survival curve. Accord-
ing to Youden's index, the maximum J value was 0.587 and
0.653, respectively (J = Sensitivity + Specificity - 1). Cutoffs
of MLR = 30.95% (Figure 1A, arrow) and MLR = 3.15%
(Figure 1B, arrow) were designated, respectively. Under
these circumstances, the sensitivity was 78.1% and 87.5%
and the specificity was 80.6% and 77.8%.
Correlation between MLR grades and prognosis
With MLR = 30.95% and MLR = 3.15% designated as cut-
offs, the MLR was defined as MLR1 (MLR<3.15%), MLR2
(3.15%  ≤ MLR ≤ 30.95%), and MLR3 (MLR>30.95%).
Univariate survival analysis suggested that a significant
difference in prognosis was found among the different
MLR groups (X2 = 36.575, P = 0.000). Postsurgery survival
time was shorter in patients with a higher MLR (Figure 2).
As shown in Table 1, multivariate risk analysis showed
that only MLR is an independent prognostic factor.
Patients with a higher MLR suffered a higher death risk
(RR = 2.801, P = 0.000, 95% CI: 1.680 – 4.668)(Table 2).
Correlation between MLR and N stage in gastric 
adenocarcinoma
As shown in Table 3, patients with the same N stage may
be in different MLR groups. Moreover, in N2 stage (JRSGC
classification), differences in the patients' prognosis were
seen among the different MLR groups (X2 = 4.372, P =
0.037) (Figure 3A). Similarly, in N1 stage (UICC classifica-
tion), differences were also observed (X2 = 4.320, P  =
0.038) (Figure 3B).
Effects of lymph node micrometastasis on the MLR in 
gastric adenocarcinoma
Lymph node micrometastasis was identified as a meta-
static focus ranging from 0.2 to 2 mm in diameter and was
mainly located at the marginal sinus with a nonclustered
or clustered distribution. Occasionally, some were also
Table 3: Correlation between MLR and N stage in gastric adenocarcinoma.
MLR groups [n (%)] MLR groups [n (%)]
N stage (UICC) Samples MLR1 MLR2 MLR3 N stage (JRSGC) Samples MLR1 MLR2 MLR3
N0 43 43(100) N0 43 43(100)
N1 44 19(43.2) 25(56.8) N1 38 16(42.1) 22(57.9)
N2 24 1(4.2) 23(95.8) N2 30 4(13.3) 26(86.7)
N3 10 10(100) N3 10 10(100)
Survival curves in patients with the same N stage, but in different MLR groups Figure 3
Survival curves in patients with the same N stage, but in different MLR groups. A. N2 stage (JRSGC classification); B. 
N1 (UICC classification).Journal of Experimental & Clinical Cancer Research 2009, 28:55 http://www.jeccr.com/content/28/1/55
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observed at the medulla or cortex. In lymph nodes with
positive HE staining, tumor cells were found gathered into
a cluster. Additionally, some lymph nodes were disrupted
by tumor cells (Figure 4).
In total, 697 lymph nodes in 45 gastric adenocarcinomas
patients were examined, with a median number of 13
nodes (ranging from seven to 46) and an average number
of 15. In all, lymph node micrometastasis was identified
in 35 of 45 patients and in 242 of 697 nodes (MLR =
34.7%, 242/697). All these nodes showed positive CK
immunohistochemical staining. Furthermore, lymph
nodes micrometastasis was identified by CK immunohis-
tochemical staining in four of 10 nodes with N0 deter-
mined by HE staining. Lymph node micrometastasis was
also identified in 61 of 455 (13.4%) lymph nodes with
negative CK immunohistochemical staining. The MLR
determined by CK staining was 43.5% (303/696). Nota-
bly, the MLR determined by HE staining and CK staining
showed a significant difference (P  = 0.001) (Table 4).
Whether identified by HE or CK staining, the MLR was
related to lymph vessel invasion and the depth of invasion
(P < 0.05) (Table 5), but was not related to gender, Lauren
classification, type of histology, and blood vessel inva-
sion.
Distribution characteristics of lymph node micrometastasis Figure 4
Distribution characteristics of lymph node micrometastasis. A. Marginal sinus type, nonclustered (×400); B. Marginal 
sinus type, clustered (×200); C. Intermediate sinus type, clustered and nonclustered (×100); D. Parenchymal type, clustered 
(×100); E. Diffuse type, clustered (×100); F. Isolated tumor cells (×400).Journal of Experimental & Clinical Cancer Research 2009, 28:55 http://www.jeccr.com/content/28/1/55
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Discussion
The prognosis was significantly related to pathological
characteristics. MLR is a simple and effective marker that
can prevent stage migration. Nonetheless, the criteria of
MLR classification need to be established [9,10]. The MLR
cutoff was designated as 20% (N0, 0%; N1, <20%; N2,
>20%) in a German gastric cancer study [9,10]. Yu and
colleagues designated the MLR cutoff as 25% in gastric
cancer patients that underwent D2 lymphadenectomy
[11]. Kodera and colleagues defined the MLR as 0%, 1% –
19%, 20% – 60% and >60% in gastric cancer patient that
underwent D2 lymphadenectomy [6]. Hyung and col-
leagues designated 10% MLR as N1 stage and 25% MLR as
N2 stage in T3 gastric cancer [5]. Additionally, the MLR
was defined as ≤ 25%, ≤ 50% and >50% [4] or 0%, 1% –
10%, 11% – 25% and >25% [3]. The MLR was also classi-
fied as 0%, 0% – 30%, 30% – 50% and >50% in a Chinese
study [2]. All the studies mentioned above demonstrated
that the MLR is an independent prognostic factor in gas-
tric cancer. However, more effective criteria for MLR clas-
sification need to be further elucidated.
The ROC curve has been extensively used to measure diag-
nostic accuracy. The ROC curve also can be used to evalu-
ate the predictive value of the scoring system [12,13]. By
using the ROC curve in the current study to determine the
cutoff, the MLR proved to be an independent prognostic
factor in gastric cancer. In the N2 stage of the JRSGC clas-
sification and N1 stage of the UICC classification, differ-
ences in prognosis were seen among the different MLR
groups. Three-year and five-year survival rates were
believed to be effective markers for gastric cancer progno-
sis. Therefore, the combined ROC curve with MLR is an
effective strategy for drawing the curve to predict three-
year and five-year survival rates.
Metastatic foci in lymph nodes, ranging from 0.2 to 2
mm, <0.2 mm, and >2 mm in diameter, were identified as
lymph node micrometastasis, isolated tumor cells (ITCs),
and lymph node metastasis, respectively [8]. Metastatic
foci in lymph nodes were in a nonclustered or clustered
distribution: a single clustered metastatic focus with a
maximum diameter ranging from 0.2 to 2 mm, multiple
clustered metastatic foci with the maximum sum of diam-
eters ranging from 0.2 to 2 mm, and nonclustered meta-
static foci with the maximum area size, including cancer
cells, ranging from 0.2 to 2 mm [14].
Lymph node metastasis is one of the most important
prognostic factors in gastric cancer. Until now, HE stain-
ing as a routine pathological examination is the good
standard for the diagnosis of lymph node metastasis.
However, the occurrences of lymph node micrometastasis
Table 5: Correlation between MLR grades and clinical characteristics.
Characteristics Samples MLR classification (HE) P MLR classification (CK) P
MLR1 MLR2 MLR3 MLR1 MLR2 MLR3
Total 45 10 12 23 6 9 30
Gender 0.607 0.508
Male 26 4 11 11 2 6 18
Female 19 6 1 12 4 3 12
Lauren type 0.823 0.870
Intestinal type 42 9 12 21 6 8 28
Diffuse type 3 1 0 2 0 1 2
Type of histology 0.808 0.833
1–2 28 5 10 13 3 7 18
3 1 7 5 21 0 3 21 2
Lymphatic vessel invasion 0.000 0.000
Negative 10 9 1 0 5 4 1
Positive 35 1 11 23 1 5 29
Blood vessel invasion 0.086 0.069
Negative 35 10 9 16 6 8 21
Positive 10 0 3 7 0 1 9
Depth of invasion 0.045 0.019
pT1–2 15 6 4 5 5 3 7
pT3–4 30 4 8 18 1 6 23
Table 4: Patients with lymph node metastasis detected by HE 
and CK staining.
Lymph node metastasis
Case No (%)
P Lymph node metastasis
LN No (%)
P
Positive Negative Positive Negative
HE 35 (77.8) 10 (22.2) 0.25 303 (43.5) 394 (56.5) 0.001
CK 39 (86.7) 6 (13.3) 242 (34.7) 455 (65.3)Journal of Experimental & Clinical Cancer Research 2009, 28:55 http://www.jeccr.com/content/28/1/55
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could not be identified by routine pathological detection.
Recent advances in immunohistochemical and molecular
biologic techniques have made it possible to detect the
lymph node micrometastasis. Cytokeratin is a component
of the cytoskeleton of epithelial cells, which dose not
present in the lymph nodes. Immunohistochemical
examination by CK20 as one of cytokeratin family and a
gene marker of tumor has been applied for longer than a
decade [15] and CK20 mRNA has also successfully been
detected in lymph nodes without metastasis in routine
histological examination [16]. In comparison with the
detection of CK20 mRNA from lymph node, the immuno-
histochemical examination of CK20 has some advantages
such as morphological observation and utilization of ret-
rospective investigation.
Morphologically, cancer cells in lymph nodes were
described as marginal sinus, intermediate sinus, paren-
chymal, and diffuse types. Marginal sinus is the most
common type. This may be due to migrant cancer cells
that were initially arrested in the marginal sinus [14,17].
In this study, metastatic foci in lymph nodes were mainly
located at the marginal sinus with a nonclustered or clus-
tered distribution, which is consistent with metastasis the-
ory. A previous study indicated that micrometastasis in
lymph nodes had proliferating activity and had the poten-
tial for developing metastasis [18].
Conclusion
In conclusion, our study suggests that the MLR is an inde-
pendent prognostic factor in gastric cancer and, when
combined with the ROC curve, is an effective strategy for
drawing a curve for predicting the 3-year and 5-year sur-
vival rates. The results of lymph node micrometastasis
make the MLR increase.
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